The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses

Diabetes, Obesity and Metabolism

Volumn 16, Issue 6, 2014, Pages 569-572

  Anz, David ^a   Kruger, S ^a   Haubner, S ^a   Rapp, M ^a   Bourquin, C ^b   Endres, S ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

DPP IV inhibitor; Drug mechanism; Pharmacology; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; SAXAGLIPTIN; SITAGLIPTIN; TOLL LIKE RECEPTOR; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDE; NITRILE; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; METABOLIC REGULATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; NORMAL HUMAN; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY;

ADAMANTANE; ADAPTIVE IMMUNITY; ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; IMMUNITY, INNATE; MICE; NITRILES; PYRAZINES; PYRROLIDINES; T-LYMPHOCYTES; TRIAZOLES;

EID: 84899630197     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12246     Document Type: Article

References (12)

1. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70: 489-512.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
3. Fox DA, Hussey RE, Fitzgerald KA et al. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984; 133: 1250-1256.
4. Buhling F, Junker U, Reinhold D, Neubert K, Jager L, Ansorge S. Functional role of CD26 on human B lymphocytes. Immunol Lett 1995; 45: 47-51.
5. Morimoto C, Torimoto Y, Levinson G et al. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol 1989; 143: 3430-3439.
6. Pacheco R, Martinez-Navio JM, Lejeune M et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci USA 2005; 102: 9583-9588.
7. Ohnuma K, Yamochi T, Uchiyama M et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci USA 2004; 101: 14186-14191.
8. Proost P, Struyf S, Schols D et al. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999; 274: 3988-3993.
9. Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets 2009; 10: 71-87.
10. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327: 291-295.
11. Netea MG, van de Veerdonk FL, van der Meer JW. Primary immunodeficiencies of pattern recognition receptors. J Intern Med 2012; 272: 517-527.
12. Goossen K, Graber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012; 14: 1061-1072.